On the other hand, nilotinib is a selective tyrosine kinase inhibitor that is 10–30 folds more potent than imatinib in the inhibition of BCR-ABL tyrosine kinase and mainly used for imatinib-resistant CML [11]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.